Fractyl Health (GUTS) Registration Filing summary

Company overview and business model

• Focuses on developing durable, disease-modifying therapies for metabolic diseases, particularly obesity and type 2 diabetes, aiming to address root causes rather than provide chronic management.

• Lead product, Revita DMR System, is an investigational outpatient procedural therapy targeting duodenal dysfunction to maintain weight loss after GLP-1 drug discontinuation; received FDA Breakthrough Device designation.

• Pipeline includes Rejuva, a locally administered AAV-based pancreatic gene therapy platform, with lead candidate RJVA-001 targeting long-term remission of T2D and obesity.

• Strategic reprioritization in early 2025 shifted resources to the REMAIN-1 pivotal study for Revita, pausing other T2D-focused programs.

Financial performance and metrics

• As of December 31, 2024, net tangible book value was $28.4 million, or $0.58 per share.

• After a $100 million offering at $1.56 per share, as adjusted net tangible book value would be $1.11 per share, with immediate dilution of $0.45 per share to new investors.

• The company’s financial statements for 2023 and 2024 were audited by Ernst & Young LLP, with a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Net proceeds from the offering will support Revita and Rejuva pipeline programs, working capital, and general corporate purposes.

• Management has broad discretion over allocation of proceeds, which may be invested in short-term, investment-grade securities pending use.